Table 2 Overall characteristics of patients with psoriatic disease
Clinical characteristics | Value (n = 30) |
|---|---|
Psoriasis history, n (%) | |
 Concomitant psoriatic arthritis | 22 (73.3) |
 Nail | 9 (30) |
 Plaque | 26 (86.6) |
 Scalp | 13 (43.3) |
 Guttate | 0 (0.0) |
 Genital | 1 (3.3) |
 Inverse | 0 (0.0) |
 Pustular | 0 (0.0) |
 Erythrodermic | 0 (0.0) |
Disease activity | |
 Disease duration (years) | |
  Mean (SD) | 18.31 (14.08) |
  Median (IQR) | 15.00 (23.0) |
 PASI | |
  Mean (SD) | 2.17 (2.98) |
  Median (IQR) | 0.45 (4.4) |
 BSA | |
  Mean (SD) | 2.43 (3.96) |
  Median (IQR) | 0 (3.0) |
 HAQ | |
  Mean (SD) | 0.67 (0.66) |
  Median (IQR) | 0.437 (1.375) |
 DLQI | |
  Mean (SD) | 5.0 (6.68) |
  Median (IQR) | 5.0 (9.0) |
 VAS Global | |
  Mean (SD) | 54.1 (28.23) |
  Median (IQR) | 56.5 (46.0) |
 VAS Pain | |
  Mean (SD) | 38.05 (28.00) |
 Median (IQR) | 27.5 (43.0) |
 Swollen joint count (66) | |
  Mean (SD) | 1.36 (3.22) |
  Median (IQR) | 0 (1.0) |
 Tender joint count (68) | |
  Mean (SD) | 2.14 (5.02) |
  Median (IQR) | 0 (1.0) |
 LEI | |
  Mean (SD) | 0.91 (1.51) |
  Median (IQR) | 0 (1.0) |
 SPARCC | |
  Mean (SD) | 0 (2.70) |
  Median (IQR) | 0 (2.0) |
 DAPSA | |
  Mean (SD) | 13.36 (10.08) |
  Median (IQR) | 12.5 (10.0) |
 PsO severity, n (%) | |
  Mild (BSA < 3% or PASI < 5) | 21 (70.0) |
  Moderate (BSA 3–10% or PASI 5–10) | 6 (20.0) |
  Severe (BSA > 10% or PASI > 10) | 3 (10.0) |
 MDA | |
  7 (VLDA achieved) | 1 (4.55) |
  5–7 (MDA achieved) | 7 (31.81) |
   < 5 (MDA not achieved) | 14 (63.64) |
 Overall activitya | |
  Not active | 11 (36.67) |
  Active | 19 (63.33) |
 Topical therapy, n (%) | |
  Glucocorticoid | 21 (70.0) |
  Calcipotriol | 1 (3.3) |
 Non-biologic systemic therapy, n (%) | |
  Phototherapy | 12 (40.0) |
  Acitretin | 5 (16.7) |
  Methotrexate | 2 (6.7) |
  Sulfasalazine | 1 (3.3) |
  Ciclosporin | 0 (0.0) |